Overview


According to FutureWise analysis the market for herpes simplex virus treatment in 2023 is US$ 1.8 billion, and is expected to reach US$ 2.16 billion by 2031 at a CAGR of 2.32%.

Herpes infection can be caused by the herpes simplex virus, HSV. This can be seen not only in the genitals and mouth but also in other parts of the body. Type 1 (HSV-1), and type 2 (HSV-2) are the two types of herpes common virus. HSV-1, also known as oral herpes, causes sores around your lips and mouth. Type 2 is genital and rectal herpes. These sores can be found in the genitals as well as around the rectum. HSV-2, the most commonly transmitted sexually, is responsible for genital herpes and other highly contagious infections. The products used to treat herpes simplex virus include Zovirax Cream (Acyclovir), Zovirax Cream (Abreva), Blistex), Docosanol Valacyclovir, and Allantoin. The infection is contagious and can be spread by saliva, vaginal secretion, or semen. It is easily contracted unknowingly. COVID-19 therapies can activate the virus in infected cells. Vaccination may also be used to worsen herpesvirus-related diseases. Older adults are more likely to get herpes and thus have a greater vulnerability to other infectious diseases.

Sexually transmitted diseases, also known as venereal disease or sperm-vaginal fluid transfer, are infections that can be caught through sexual activity. STDs can be caused by bacteria, yeast, parasites, and virus. STDs can cause skin rashes, vaginal ulcers, intestinal aches, and warts. STDs can be identified by physical examination, assays such as ELISA (Enzyme-Linked Immunosorbent Assay), blood sample, fast plasma, antibody-absorption test, and a blood sample. Although herpes can affect any area of the body, the most common are the genitals or mouth. HSV-1, which causes cold sores and blisters on the lips and face, is the most common form of herpes simplex virus. HSV-2 is the virus that causes genital and genital herpes. It is responsible for most outbreaks. The most prevalent cases were found in African-American women. HSV-1 is rare and can cause genital herpes, which is an infection in the genital area or anal. HSV-2, the most common sexually transmitted infection (GH), is also the most contagious. HSV-2 infection may be fatal or chronic. HSV-2-infected patients are more likely than others to contract the human immunodeficiency virus (HIV). Multiple sources indicate that HSV incidence in low- and mid-income areas is higher. Around 80% of herpes infections are not visible. Asymptomatic infections are characterized by painful urination, blistering sores, and swelling of the lymphatic system. It is not known what the latency period is and how HSV reactivates.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Herpes Simplex Virus Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Herpes Simplex Virus Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Agenus Inc
  • AiCuris GmbHCo. KG
  • Astellas Pharma Inc
  • BioVex
  • Clinigen Group
  • Cytogenix Inc
  • Genocea Biosciences
  • GalxoSmithKline Plc
  • Lumavita AG
  • NanoBio Corporation
  • NanoViricides Inc
  • Novartis International AG
  • Sanofi
  • Starpharma Holdings Limited
  • Vical

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Treatment

  • Herpes Simples Virus-1 infection
  • Herpes Simples Virus-2 infection
  • Others

By Type

  • Oral
  • Injectable
  • Topical

By Distribution Channel

  • Hospital Pharmacy
  • Drug Store
  • Retail Store
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Herpes Simplex Virus Treatment Market By Treatment, By Type, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to:sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Herpes Simplex Virus Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Herpes Simplex Virus Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Herpes Simplex Virus Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Herpes Simplex Virus Treatment Market, By Treatment Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Herpes Simples Virus-1 infection
        2. Herpes Simples Virus-2 infection
        3. Others

  • 8.   Herpes Simplex Virus Treatment Market, By Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Oral
        2. Injectable
        3. Topical

  • 9.   Herpes Simplex Virus Treatment Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacy
        2. Drug Store
        3. Retail Store
        4. Online Pharmacy

  • 10.   North America Herpes Simplex Virus Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.   Latin America Herpes Simplex Virus Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.   Europe Herpes Simplex Virus Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.   Asia Pacific Herpes Simplex Virus Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Agenus Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AiCuris GmbHCo. KG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Astellas Pharma Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. BioVex
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Clinigen Group
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cytogenix Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Genocea Biosciences
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. GalxoSmithKline Plc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Lumavita AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. NanoBio Corporation
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. NanoViricides Inc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
            11.4. Financial Overview
         11.5. Strategic Overview
        12. Novartis International AG
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Sanofi
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14.Starpharma Holdings Limited
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
            14.5. Strategic Overview
          15. Vical
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients